Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Acquired by Federated Hermes Inc.

Federated Hermes Inc. boosted its stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 535.5% during the 4th quarter, HoldingsChannel.com reports. The fund owned 35,963 shares of the biopharmaceutical company’s stock after purchasing an additional 30,304 shares during the period. Federated Hermes Inc.’s holdings in Regeneron Pharmaceuticals were worth $25,618,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Integrated Wealth Concepts LLC raised its stake in shares of Regeneron Pharmaceuticals by 40.1% during the third quarter. Integrated Wealth Concepts LLC now owns 748 shares of the biopharmaceutical company’s stock worth $786,000 after purchasing an additional 214 shares during the last quarter. EP Wealth Advisors LLC increased its stake in Regeneron Pharmaceuticals by 16.6% in the 3rd quarter. EP Wealth Advisors LLC now owns 1,467 shares of the biopharmaceutical company’s stock valued at $1,542,000 after buying an additional 209 shares during the period. MML Investors Services LLC raised its position in Regeneron Pharmaceuticals by 13.9% during the 3rd quarter. MML Investors Services LLC now owns 5,315 shares of the biopharmaceutical company’s stock worth $5,587,000 after buying an additional 648 shares during the last quarter. M&T Bank Corp raised its position in Regeneron Pharmaceuticals by 4.3% during the 3rd quarter. M&T Bank Corp now owns 5,480 shares of the biopharmaceutical company’s stock worth $5,761,000 after buying an additional 224 shares during the last quarter. Finally, Vestcor Inc lifted its stake in shares of Regeneron Pharmaceuticals by 3.1% in the 3rd quarter. Vestcor Inc now owns 21,590 shares of the biopharmaceutical company’s stock worth $22,696,000 after acquiring an additional 654 shares during the period. 83.31% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several research analysts recently issued reports on the stock. Sanford C. Bernstein cut their price target on shares of Regeneron Pharmaceuticals from $1,110.00 to $1,070.00 and set an “outperform” rating for the company in a report on Tuesday, January 7th. Bernstein Bank cut their target price on Regeneron Pharmaceuticals from $1,070.00 to $1,000.00 in a research note on Tuesday, February 4th. Citigroup decreased their price target on Regeneron Pharmaceuticals from $795.00 to $750.00 and set a “neutral” rating on the stock in a research note on Tuesday, January 28th. Canaccord Genuity Group cut Regeneron Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, December 17th. Finally, Leerink Partners upgraded shares of Regeneron Pharmaceuticals from a “market perform” rating to an “outperform” rating and boosted their target price for the stock from $762.00 to $834.00 in a research report on Wednesday, February 5th. One analyst has rated the stock with a sell rating, six have issued a hold rating, seventeen have assigned a buy rating and two have given a strong buy rating to the company’s stock. According to MarketBeat.com, Regeneron Pharmaceuticals has an average rating of “Moderate Buy” and a consensus price target of $966.88.

Regeneron Pharmaceuticals Trading Down 2.8 %

Shares of REGN stock opened at $556.81 on Wednesday. Regeneron Pharmaceuticals, Inc. has a twelve month low of $546.36 and a twelve month high of $1,211.20. The company has a market capitalization of $60.87 billion, a price-to-earnings ratio of 14.55, a PEG ratio of 2.34 and a beta of 0.44. The firm has a 50-day moving average price of $669.26 and a 200 day moving average price of $766.90. The company has a current ratio of 4.73, a quick ratio of 3.95 and a debt-to-equity ratio of 0.09.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its quarterly earnings data on Tuesday, February 4th. The biopharmaceutical company reported $12.07 earnings per share (EPS) for the quarter, beating the consensus estimate of $11.21 by $0.86. The business had revenue of $3.79 billion for the quarter, compared to the consensus estimate of $3.76 billion. Regeneron Pharmaceuticals had a net margin of 31.07% and a return on equity of 16.32%. The company’s quarterly revenue was up 10.3% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $11.86 earnings per share. Research analysts forecast that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Thursday, March 20th. Stockholders of record on Thursday, February 20th were given a $0.88 dividend. This represents a $3.52 dividend on an annualized basis and a dividend yield of 0.63%. The ex-dividend date of this dividend was Thursday, February 20th. Regeneron Pharmaceuticals’s dividend payout ratio is currently 2.30%.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.